skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Dual Allosteric Inhibition of SHP2 Phosphatase

Journal Article · · ACS Chemical Biology

SHP2 is a cytoplasmic protein tyrosine phosphatase encoded by the PTPN11 gene and is involved in cell proliferation, differentiation, and survival. Recently, we reported an allosteric mechanism of inhibition that stabilizes the auto-inhibited conformation of SHP2. SHP099 (1) was identified and characterized as a moderately potent, orally bioavailable, allosteric small molecule inhibitor, which binds to a tunnel-like pocket formed by the confluence of three domains of SHP2. In this report, we describe further screening strategies that enabled the identification of a second, distinct small molecule allosteric site. SHP244 (2) was identified as a weak inhibitor of SHP2 with modest thermal stabilization of the enzyme. X-ray crystallography revealed that 2 binds and stabilizes the inactive, closed conformation of SHP2, at a distinct, previously unexplored binding site—a cleft formed at the interface of the N-terminal SH2 and PTP domains. Derivatization of 2 using structure-based design resulted in an increase in SHP2 thermal stabilization, biochemical inhibition, and subsequent MAPK pathway modulation. Downregulation of DUSP6 mRNA, a downstream MAPK pathway marker, was observed in KYSE-520 cancer cells. Remarkably, simultaneous occupation of both allosteric sites by 1 and 2 was possible, as characterized by cooperative biochemical inhibition experiments and X-ray crystallography. Combining an allosteric site 1 inhibitor with an allosteric site 2 inhibitor led to enhanced pharmacological pathway inhibition in cells. This work illustrates a rare example of dual allosteric targeted protein inhibition, demonstrates screening methodology and tactics to identify allosteric inhibitors, and enables further interrogation of SHP2 in cancer and related pathologies.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
AC02–06CH11357
OSTI ID:
1435825
Journal Information:
ACS Chemical Biology, Vol. 13, Issue 3; ISSN 1554-8929
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH
Citation Metrics:
Cited by: 76 works
Citation information provided by
Web of Science

References (39)

Crystal Structure of the Tyrosine Phosphatase SHP-2 journal February 1998
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2 journal March 1998
Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains journal February 1995
Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis journal June 2014
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome journal November 2001
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia journal April 2003
The tyrosine phosphatase Shp2 (PTPN11) in cancer journal February 2008
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors journal January 2008
Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2 journal April 2016
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase journal October 2006
Protein tyrosine phosphatase function: the substrate perspective journal January 2007
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis journal November 2015
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment journal December 2014
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition journal March 2017
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer journal June 2012
Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. journal December 1992
Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention journal August 2014
Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery journal June 2010
Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) journal February 2010
Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase journal July 2014
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction journal January 2014
Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases journal June 2015
Selective Detection of Allosteric Phosphatase Inhibitors journal April 2013
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases journal June 2016
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor journal July 2016
Identifying and Characterizing Binding Sites and Assessing Druggability journal January 2009
New Method for Fast and Accurate Binding-site Identification and Analysis journal February 2007
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2 journal December 2017
Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment journal December 2017
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders journal January 2009
Minireview: Not Picking Pockets: Nuclear Receptor Alternate-Site Modulators (NRAMs) journal April 2010
The extraordinary ligand binding properties of human serum albumin journal December 2005
Simultaneous Binding of Two Different Drugs in the Binding Pocket of the Human Multidrug Resistance P-glycoprotein journal October 2003
Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein journal July 2004
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 journal March 2017
ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia journal December 2014
Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments journal March 2013
XDS journal January 2010
Features and development of Coot journal March 2010

Cited By (11)

Exploring the effect of E76K mutation on SHP2 cause gain‐of‐function activity by a molecular dynamics study journal August 2018
Synthesis, activity evaluation, and pro-apoptotic properties of novel 1,2,4-triazol-3-amine derivatives as potent anti-lung cancer agents journal January 2019
Design, Synthesis, and In Vitro Activity of Pyrazine Compounds journal December 2019
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2 journal October 2018
Exploring the effect of N308D mutation on protein tyrosine phosphatase‐2 cause gain‐of‐function activity by a molecular dynamics study journal October 2018
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition journal October 2018
Synthesis, activity evaluation, and pro-apoptotic properties of novel 1,2,4-triazol-3-amine derivatives as potent anti-lung cancer agents text January 2019
Synthesis, activity evaluation, and pro-apoptotic properties of novel 1,2,4-triazol-3-amine derivatives as potent anti-lung cancer agents text January 2019
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR journal January 2020
Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2 journal December 2018
Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity journal November 2019

Figures / Tables (8)